Efficacy of Suvorexant on Post-operative Sleep Disturbance
Фаза 4
Завершено
NCT05823844
| Заболевание | Postoperative Insomnia, Postoperative Delirium |
|---|
| Фаза | Фаза 4 |
|---|
| Спонсор | Columbia University |
|---|
| Статус | Завершено |
|---|
| Участники | 100 участн. |
|---|
| Вмешательство | Suvorexant |
|---|
| Дата начала | 1.05.2023 |
|---|
| Дата завершения | 6.11.2025 |
|---|
| Публикация результатов | 23.07.2026 |
|---|
Кратко
The study is a parallel group, double blind, randomized trial. Subjects will be recruited from individuals undergoing elective surgery for orthopedic, abdominal, urologic, gynecologic or spine reasons. Out of 92 subjects, one experimental group of 46 subjects will receive 20 mg Suvorexant beginning the first in-hospital night ("day 0") and continuing for their hospital stay. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant. For blinding purposes each arm will receive two tablets (two 10 mg tablets or one 10 mg tablet and a placebo). The other control group of 46 subjects will receive placebo (two tablets) and treatment as usual.
Total Sleep Time on Day 0 (TST)
Day 0 of in-hospital stay after surgery · Total Sleep Time (Hours)
| Suvorexant Administration | 4.3 ± 2.287 Total Sleep Time (Hours) |
|---|
| Placebo Administration | 4.3 ± 2.327 Total Sleep Time (Hours) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.